http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103898205-B

Outgoing Links

Predicate Object
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-8139
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57438
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57446
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57484
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-38
filingDate 2013-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2016-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2016-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-103898205-B
titleOfInvention The application of CST1
abstract Do you the invention discloses CST1 (Cystatin? does is SN) novelty teabag, specially Cystatin? the application of SN in preparation diagnosis and Hepatocellular Carcinoma Be Indicated, gastrointestinal stromal tumors (GISTs), carcinoma of the pancreas or esophageal carcinoma mark; The invention also discloses the trapping agent of diagnosis and Hepatocellular Carcinoma Be Indicated, gastrointestinal stromal tumors (GISTs), carcinoma of the pancreas or esophageal carcinoma mark, and by trapping agent for the preparation of diagnosis and the test kit of Hepatocellular Carcinoma Be Indicated, gastrointestinal stromal tumors (GISTs), carcinoma of the pancreas or the esophageal carcinoma, obtained test kit has that specificity is good, sensitivity advantages of higher, can be used in the curative effect evaluation in the early diagnosis of liver cancer, gastrointestinal stromal tumors (GISTs), carcinoma of the pancreas or the esophageal carcinoma, therapeutic process and the transfer recurrence monitoring after treatment.
priorityDate 2013-05-07-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID449630271
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID9986
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID414865888
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5291
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID1469
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9702
http://rdf.ncbi.nlm.nih.gov/pubchem/taxonomy/TAXID9606
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60960
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419555088
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID171548
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID9986
http://rdf.ncbi.nlm.nih.gov/pubchem/anatomy/ANATOMYID9606
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419534036

Total number of triples: 32.